DNLI
Price
$12.71
Change
+$0.16 (+1.27%)
Updated
Apr 17, 04:13 PM (EDT)
Capitalization
1.82B
26 days until earnings call
IDYA
Price
$16.82
Change
+$0.64 (+3.96%)
Updated
Apr 17, 04:24 PM (EDT)
Capitalization
1.42B
26 days until earnings call
Ad is loading...

DNLI vs IDYA

Header iconDNLI vs IDYA Comparison
Open Charts DNLI vs IDYABanner chart's image
Denali Therapeutics
Price$12.71
Change+$0.16 (+1.27%)
Volume$500
Capitalization1.82B
IDEAYA Biosciences
Price$16.82
Change+$0.64 (+3.96%)
Volume$3.04K
Capitalization1.42B
DNLI vs IDYA Comparison Chart
Loading...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DNLI vs. IDYA commentary
Apr 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a Hold and IDYA is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 18, 2025
Stock price -- (DNLI: $12.55 vs. IDYA: $16.18)
Brand notoriety: DNLI and IDYA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 104% vs. IDYA: 99%
Market capitalization -- DNLI: $1.82B vs. IDYA: $1.42B
DNLI [@Biotechnology] is valued at $1.82B. IDYA’s [@Biotechnology] market capitalization is $1.42B. The market cap for tickers in the [@Biotechnology] industry ranges from $287.04B to $0. The average market capitalization across the [@Biotechnology] industry is $2.08B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 0 FA rating(s) are green whileIDYA’s FA Score has 0 green FA rating(s).

  • DNLI’s FA Score: 0 green, 5 red.
  • IDYA’s FA Score: 0 green, 5 red.
According to our system of comparison, IDYA is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 5 TA indicator(s) are bullish while IDYA’s TA Score has 4 bullish TA indicator(s).

  • DNLI’s TA Score: 5 bullish, 3 bearish.
  • IDYA’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, DNLI is a better buy in the short-term than IDYA.

Price Growth

DNLI (@Biotechnology) experienced а -2.41% price change this week, while IDYA (@Biotechnology) price change was +2.53% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.87%. For the same industry, the average monthly price growth was -13.52%, and the average quarterly price growth was -24.87%.

Reported Earning Dates

DNLI is expected to report earnings on Jul 31, 2025.

IDYA is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+6.87% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($1.82B) has a higher market cap than IDYA($1.42B). IDYA (-37.043) and DNLI (-38.420) have similar YTD gains . IDYA has higher annual earnings (EBITDA): -323.14M vs. DNLI (-492.89M). DNLI has more cash in the bank: 832M vs. IDYA (676M). IDYA has less debt than DNLI: IDYA (19.2M) vs DNLI (48.7M). IDYA has higher revenues than DNLI: IDYA (7M) vs DNLI (0).
DNLIIDYADNLI / IDYA
Capitalization1.82B1.42B129%
EBITDA-492.89M-323.14M153%
Gain YTD-38.420-37.043104%
P/E RatioN/AN/A-
Revenue07M-
Total Cash832M676M123%
Total Debt48.7M19.2M254%
FUNDAMENTALS RATINGS
DNLI vs IDYA: Fundamental Ratings
DNLI
IDYA
OUTLOOK RATING
1..100
5856
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
60
Fair valued
PROFIT vs RISK RATING
1..100
10065
SMR RATING
1..100
9595
PRICE GROWTH RATING
1..100
8887
P/E GROWTH RATING
1..100
98100
SEASONALITY SCORE
1..100
n/a95

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IDYA's Valuation (60) in the null industry is somewhat better than the same rating for DNLI (94) in the Biotechnology industry. This means that IDYA’s stock grew somewhat faster than DNLI’s over the last 12 months.

IDYA's Profit vs Risk Rating (65) in the null industry is somewhat better than the same rating for DNLI (100) in the Biotechnology industry. This means that IDYA’s stock grew somewhat faster than DNLI’s over the last 12 months.

IDYA's SMR Rating (95) in the null industry is in the same range as DNLI (95) in the Biotechnology industry. This means that IDYA’s stock grew similarly to DNLI’s over the last 12 months.

IDYA's Price Growth Rating (87) in the null industry is in the same range as DNLI (88) in the Biotechnology industry. This means that IDYA’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's P/E Growth Rating (98) in the Biotechnology industry is in the same range as IDYA (100) in the null industry. This means that DNLI’s stock grew similarly to IDYA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNLIIDYA
RSI
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
77%
Momentum
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
81%
MACD
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
77%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 4 days ago
78%
Bullish Trend 4 days ago
76%
Declines
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
76%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
82%
Aroon
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
82%
View a ticker or compare two or three
Ad is loading...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
BTC.X84033.870000364.875000
+0.44%
Bitcoin cryptocurrency
GME26.25-0.45
-1.69%
GameStop Corp
SPY525.66-11.95
-2.22%
SPDR® S&P 500® ETF
AAPL194.27-7.87
-3.89%
Apple
TSLA241.55-12.56
-4.94%
Tesla

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with ARWR. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then ARWR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
-4.71%
ARWR - DNLI
58%
Loosely correlated
-11.81%
BEAM - DNLI
58%
Loosely correlated
-3.82%
RCKT - DNLI
58%
Loosely correlated
-5.82%
NTLA - DNLI
56%
Loosely correlated
-6.79%
RGNX - DNLI
55%
Loosely correlated
-5.95%
More

IDYA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with IMNM. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then IMNM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDYA
1D Price
Change %
IDYA100%
-4.71%
IMNM - IDYA
53%
Loosely correlated
-3.11%
KRYS - IDYA
53%
Loosely correlated
-2.62%
RCKT - IDYA
53%
Loosely correlated
-5.82%
XENE - IDYA
52%
Loosely correlated
+2.27%
DNLI - IDYA
52%
Loosely correlated
-4.71%
More